[S02DA03, antipyrine, Antipyrine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Arsenic trioxide.]
[J01GA01, streptomycin, Arsenic trioxide may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Arsenic trioxide.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Arsenic trioxide.]
[L04AA27, fingolimod, Arsenic trioxide may increase the immunosuppressive activities of Fingolimod.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01CG01, sulbactam, Arsenic trioxide may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Arsenic trioxide.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Arsenic trioxide.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Arsenic trioxide.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Arsenic trioxide.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Arsenic trioxide.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Arsenic trioxide.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Arsenic trioxide.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Arsenic trioxide.]
[L02BA01, tamoxifen, The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Arsenic trioxide.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L01CB02, teniposide, The risk or severity of adverse effects can be increased when Teniposide is combined with Arsenic trioxide.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Arsenic trioxide.]
[B01AE07, dabigatran etexilate, The serum concentration of Dabigatran etexilate can be increased when it is combined with Arsenic trioxide.]
[G03BA03, testosterone, Testosterone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Tetracaine.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Arsenic trioxide.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Arsenic trioxide.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Arsenic trioxide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Eribulin.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Arsenic trioxide.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Arsenic trioxide.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Thioridazine is combined with Arsenic trioxide.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Arsenic trioxide.]
[G04BE06, moxisylyte, Arsenic trioxide may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Arsenic trioxide may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Arsenic trioxide.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Arsenic trioxide.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[S01AA12, tobramycin, Arsenic trioxide may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Arsenic trioxide.]
[M02AX02, tolazoline, The risk or severity of adverse effects can be increased when Tolazoline is combined with Arsenic trioxide.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Arsenic trioxide.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N02AX02, tramadol, Tramadol may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the orthostatic hypotensive activities of Arsenic trioxide.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Arsenic trioxide.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Arsenic trioxide.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Arsenic trioxide.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Arsenic trioxide.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Triazolam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX12, trientine, Arsenic trioxide may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Arsenic trioxide.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Arsenic trioxide.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Arsenic trioxide.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Arsenic trioxide.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Arsenic trioxide.]
[C02BA01, trimethaphan, Arsenic trioxide may increase the hypotensive activities of Trimethaphan.]
[J01EA01, trimethoprim, Trimethoprim may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Arsenic trioxide.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Arsenic trioxide.]
[C09CA09, azilsartan medoxomil, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Azilsartan medoxomil.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Arsenic trioxide.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Belimumab.]
[L01FX04, ipilimumab, Arsenic trioxide may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Vandetanib.]
[R02AA14, oxyquinoline, Arsenic trioxide may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Arsenic trioxide.]
[J05AP02, telaprevir, The serum concentration of Telaprevir can be increased when it is combined with Arsenic trioxide.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Arsenic trioxide.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Arsenic trioxide.]
[S01AA28, vancomycin, Arsenic trioxide may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Belatacept.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Arsenic trioxide.]
[B01AF01, rivaroxaban, The serum concentration of Rivaroxaban can be increased when it is combined with Arsenic trioxide.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Arsenic trioxide.]
[B01AC24, ticagrelor, The serum concentration of Ticagrelor can be increased when it is combined with Arsenic trioxide.]
[C08DA01, verapamil, The risk or severity of adverse effects can be increased when Verapamil is combined with Arsenic trioxide.]
[N06AX09, viloxazine, Arsenic trioxide may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be increased when it is combined with Arsenic trioxide.]
[C04AX07, vincamine, Arsenic trioxide may increase the hypotensive activities of Vincamine.]
[L01CA02, vincristine, The excretion of Vincristine can be decreased when combined with Arsenic trioxide.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Arsenic trioxide.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Arsenic trioxide.]
[B01AA03, warfarin, Arsenic trioxide may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Arsenic trioxide.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Zuclopenthixol.]
[L01EC01, vemurafenib, The serum concentration of Vemurafenib can be increased when it is combined with Arsenic trioxide.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Arsenic trioxide.]
[M05BA05, tiludronic acid, Tiludronic acid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[B06AC02, icatibant, Arsenic trioxide may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The serum concentration of Crizotinib can be increased when it is combined with Arsenic trioxide.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Arsenic trioxide.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Arsenic trioxide.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Trovafloxacin is combined with Arsenic trioxide.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Arsenic trioxide may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Arsenic trioxide.]
[N02BA01, aspirin, The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Arsenic trioxide.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ruxolitinib.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Arsenic trioxide.]
[J01DH04, doripenem, Arsenic trioxide may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, The risk or severity of adverse effects can be increased when Atenolol is combined with Arsenic trioxide.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Arsenic trioxide.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Arsenic trioxide.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Arsenic trioxide.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Arsenic trioxide.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Arsenic trioxide.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Arsenic trioxide.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Arsenic trioxide.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Arsenic trioxide.]
[L01BC05, gemcitabine, The serum concentration of Gemcitabine can be increased when it is combined with Arsenic trioxide.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Arsenic trioxide.]
[M03BX01, baclofen, Baclofen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Arsenic trioxide.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Arsenic trioxide.]
[L01FD02, pertuzumab, The risk or severity of cardiotoxicity can be increased when Arsenic trioxide is combined with Pertuzumab.]
[A08AA11, lorcaserin, Arsenic trioxide may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Arsenic trioxide.]
[L01XG02, carfilzomib, The serum concentration of Carfilzomib can be increased when it is combined with Arsenic trioxide.]
[L02BB04, enzalutamide, Arsenic trioxide may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Arsenic trioxide.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Arsenic trioxide.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Aldosterone.]
[L01EX05, regorafenib, The serum concentration of Regorafenib can be increased when it is combined with Arsenic trioxide.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Arsenic trioxide.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may decrease the cardiotoxic activities of Arsenic trioxide.]
[D02BA02, octinoxate, Arsenic trioxide may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Arsenic trioxide.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Arsenic trioxide.]
[N04BD02, rasagiline, Rasagiline may increase the orthostatic hypotensive activities of Arsenic trioxide.]
[C08CA13, lercanidipine, The risk or severity of adverse effects can be increased when Lercanidipine is combined with Arsenic trioxide.]
[L04AA29, tofacitinib, Arsenic trioxide may increase the immunosuppressive activities of Tofacitinib.]
[V09IX04, fluorodeoxyglucose F18, Arsenic trioxide may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Arsenic trioxide.]
[G04BE03, sildenafil, The serum concentration of Sildenafil can be increased when it is combined with Arsenic trioxide.]
[V08CA11, gadofosveset, Arsenic trioxide may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ponatinib.]
[B01AF02, apixaban, The serum concentration of Apixaban can be increased when it is combined with Arsenic trioxide.]
[A16AX08, teduglutide, Arsenic trioxide may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Arsenic trioxide.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Arsenic trioxide.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Arsenic trioxide.]
[A16AX09, glycerol phenylbutyrate, Arsenic trioxide may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Arsenic trioxide.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Arsenic trioxide.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Dimethyl fumarate.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Arsenic trioxide.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Arsenic trioxide.]
[A06AX06, tegaserod, The serum concentration of Tegaserod can be increased when it is combined with Arsenic trioxide.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Arsenic trioxide.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Benzocaine.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be decreased when used in combination with Arsenic trioxide.]
[L03AA12, ancestim, Arsenic trioxide may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L04AA18, everolimus, The serum concentration of Everolimus can be increased when it is combined with Arsenic trioxide.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Arsenic trioxide.]
[L01EC02, dabrafenib, The serum concentration of Dabrafenib can be increased when it is combined with Arsenic trioxide.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L01EE01, trametinib, Arsenic trioxide may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Arsenic trioxide may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[L01EB03, afatinib, The serum concentration of Afatinib can be increased when it is combined with Arsenic trioxide.]
[N06AX28, levomilnacipran, Arsenic trioxide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J05AJ03, dolutegravir, The serum concentration of Dolutegravir can be increased when it is combined with Arsenic trioxide.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Bepridil.]
[C02KX05, riociguat, The serum concentration of Riociguat can be increased when it is combined with Arsenic trioxide.]
[L03AA14, lipegfilgrastim, Arsenic trioxide may increase the myelosuppressive activities of Lipegfilgrastim.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Arsenic trioxide.]
[C02KX04, macitentan, Arsenic trioxide may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ibrutinib.]
[N06AX26, vortioxetine, Arsenic trioxide may decrease the excretion rate of Vortioxetine which could result in a higher serum level.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J05AP05, simeprevir, The serum concentration of Simeprevir can be increased when it is combined with Arsenic trioxide.]
[J05AP08, sofosbuvir, The serum concentration of Sofosbuvir can be increased when it is combined with Arsenic trioxide.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Arsenic trioxide.]
[C01CA27, droxidopa, Arsenic trioxide may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[C07AB04, acebutolol, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Acebutolol.]
[N05CH03, tasimelteon, Arsenic trioxide may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Apremilast.]
[L02BG02, formestane, Arsenic trioxide may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Arsenic trioxide.]
[S01ED02, betaxolol, The risk or severity of adverse effects can be increased when Betaxolol is combined with Arsenic trioxide.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Arsenic trioxide.]
[V03AB34, fomepizole, Arsenic trioxide may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C02CC01, bethanidine, Arsenic trioxide may increase the hypotensive activities of Bethanidine.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Arsenic trioxide.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Siltuximab.]
[L01ED02, ceritinib, The serum concentration of Ceritinib can be increased when it is combined with Arsenic trioxide.]
[B01AC26, vorapaxar, The risk or severity of bleeding can be increased when Vorapaxar is combined with Arsenic trioxide.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Vedolizumab.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Arsenic trioxide.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Arsenic trioxide.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Belinostat.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Idelalisib.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Arsenic trioxide.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Arsenic trioxide.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Peginterferon beta-1a.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Eliglustat.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Arsenic trioxide.]
[A06AH03, naloxegol, The serum concentration of Naloxegol can be increased when it is combined with Arsenic trioxide.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Pirfenidone.]
[L01EX09, nintedanib, The serum concentration of Nintedanib can be increased when it is combined with Arsenic trioxide.]
[S03AA06, gentamicin, Arsenic trioxide may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Blinatumomab.]
[J05AP09, dasabuvir, The serum concentration of Dasabuvir can be increased when it is combined with Arsenic trioxide.]
[L01XK01, olaparib, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dicoumarol is combined with Arsenic trioxide.]
[B01AF03, edoxaban, The serum concentration of Edoxaban can be increased when it is combined with Arsenic trioxide.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Arsenic trioxide.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Palbociclib.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Arsenic trioxide.]
[L01XH03, panobinostat, The serum concentration of Panobinostat can be increased when it is combined with Arsenic trioxide.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Arsenic trioxide.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Tioclomarol is combined with Arsenic trioxide.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Ivabradine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Arsenic trioxide.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Arsenic trioxide.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Arsenic trioxide.]
[V03AB37, idarucizumab, Arsenic trioxide may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Trabectedin.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Mepolizumab.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be increased when it is combined with Arsenic trioxide.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Arsenic trioxide.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Arsenic trioxide.]
[L01XG03, ixazomib, Arsenic trioxide may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[B01AC27, selexipag, The serum concentration of Selexipag can be increased when it is combined with Arsenic trioxide.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Arsenic trioxide.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Arsenic trioxide.]
[M04AB05, lesinurad, Arsenic trioxide may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[J05AP10, elbasvir, The serum concentration of Elbasvir can be increased when it is combined with Arsenic trioxide.]
[J05AP11, grazoprevir, The serum concentration of Grazoprevir can be increased when it is combined with Arsenic trioxide.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N03AX23, brivaracetam, Arsenic trioxide may decrease the excretion rate of Brivaracetam which could result in a higher serum level.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ixekizumab.]
[L01XX52, venetoclax, The serum concentration of Venetoclax can be increased when it is combined with Arsenic trioxide.]
[N05BA08, bromazepam, Arsenic trioxide may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Arsenic trioxide.]
[A02AD05, aluminum magnesium silicate, Arsenic trioxide may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Arsenic trioxide.]
[C08CA01, amlodipine, The risk or severity of adverse effects can be increased when Amlodipine is combined with Arsenic trioxide.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Bupivacaine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Arsenic trioxide.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Arsenic trioxide.]
[N05BE01, buspirone, Buspirone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Busulfan is combined with Arsenic trioxide.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Antilymphocyte immunoglobulin (horse).]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Artemether.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Arsenic trioxide.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Arsenic trioxide.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Brodalumab.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Arsenic trioxide.]
[A06AH05, naldemedine, Arsenic trioxide may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Arsenic trioxide.]
[C09AA07, benazepril, The risk or severity of adverse effects can be increased when Benazepril is combined with Arsenic trioxide.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Arsenic trioxide.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Oxybuprocaine.]
[P01CA02, benznidazole, Arsenic trioxide may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Arsenic trioxide.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Arsenic trioxide.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J05AE09, tipranavir, The serum concentration of Tipranavir can be increased when it is combined with Arsenic trioxide.]
[N07XX13, valbenazine, Arsenic trioxide may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Arsenic trioxide.]
[N04BD03, safinamide, Safinamide may increase the orthostatic hypotensive activities of Arsenic trioxide.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Sarilumab.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Arsenic trioxide.]
[B01AF04, betrixaban, The serum concentration of Betrixaban can be increased when it is combined with Arsenic trioxide.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Capecitabine is combined with Arsenic trioxide.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Arsenic trioxide.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Vorinostat.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Arsenic trioxide.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Arsenic trioxide.]
[C07AB07, bisoprolol, The serum concentration of Bisoprolol can be increased when it is combined with Arsenic trioxide.]
[J05AG03, efavirenz, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Arsenic trioxide.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Arsenic trioxide.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Arsenic trioxide.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Arsenic trioxide.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nesiritide.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Arsenic trioxide.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Arsenic trioxide.]
[C01AA02, acetyldigoxins, Arsenic trioxide may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be decreased when used in combination with Arsenic trioxide.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Arsenic trioxide.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Arsenic trioxide.]
[C09AA01, captopril, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Captopril.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Macimorelin.]
[L02BB05, apalutamide, Arsenic trioxide may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Carbamazepine is combined with Arsenic trioxide.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Arsenic trioxide.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Arsenic trioxide.]
[C07AG02, carvedilol, The risk or severity of adverse effects can be increased when Carvedilol is combined with Arsenic trioxide.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Arsenic trioxide.]
[B02BX08, avatrombopag, The serum concentration of Avatrombopag can be increased when it is combined with Arsenic trioxide.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Baricitinib.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Arsenic trioxide.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Arsenic trioxide.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01GB14, plazomicin, Arsenic trioxide may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Arsenic trioxide.]
[H01CC03, elagolix, The serum concentration of Elagolix can be increased when it is combined with Arsenic trioxide.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Ivosidenib.]
[A16AX14, migalastat, Arsenic trioxide may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, Arsenic trioxide may decrease the excretion rate of Stiripentol which could result in a higher serum level.]
[B02BX07, lusutrombopag, The serum concentration of Lusutrombopag can be increased when it is combined with Arsenic trioxide.]
[L01EM04, duvelisib, The serum concentration of Duvelisib can be increased when it is combined with Arsenic trioxide.]
[L01EB07, dacomitinib, The serum concentration of Dacomitinib can be increased when it is combined with Arsenic trioxide.]
[J01AA15, omadacycline, The serum concentration of Omadacycline can be increased when it is combined with Arsenic trioxide.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Arsenic trioxide.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Arsenic trioxide.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Arsenic trioxide may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Arsenic trioxide.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Arsenic trioxide.]
[R03BB08, revefenacin, The serum concentration of Revefenacin can be increased when it is combined with Arsenic trioxide.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Arsenic trioxide.]
[L01EX12, larotrectinib, The serum concentration of Larotrectinib can be increased when it is combined with Arsenic trioxide.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Arsenic trioxide.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Arsenic trioxide.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ravulizumab.]
[A06AX05, prucalopride, The serum concentration of Prucalopride can be increased when it is combined with Arsenic trioxide.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Arsenic trioxide.]
[C09AA08, cilazapril, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Cilazapril.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Arsenic trioxide.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Arsenic trioxide.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Arsenic trioxide.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Siponimod.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Arsenic trioxide.]
[N06BA14, solriamfetol, Arsenic trioxide may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[N05BA09, clobazam, The serum concentration of Clobazam can be increased when it is combined with Arsenic trioxide.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Cloprednol.]
[C09CA06, candesartan, Arsenic trioxide may increase the hypotensive activities of Candesartan.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Arsenic trioxide.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Risankizumab.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L02BB06, darolutamide, The serum concentration of Darolutamide can be increased when it is combined with Arsenic trioxide.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Arsenic trioxide.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Upadacitinib.]
[L01EJ02, fedratinib, The serum concentration of Fedratinib can be increased when it is combined with Arsenic trioxide.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Entrectinib.]
[N07XX11, pitolisant, Arsenic trioxide may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Arsenic trioxide.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Arsenic trioxide.]
[J01XX09, daptomycin, The serum concentration of Daptomycin can be increased when it is combined with Arsenic trioxide.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Arsenic trioxide.]
[N02CC08, lasmiditan, The serum concentration of Lasmiditan can be increased when it is combined with Arsenic trioxide.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Diroximel fumarate.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[M09AX08, golodirsen, Arsenic trioxide may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Arsenic trioxide.]
[L01FX13, enfortumab vedotin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Arsenic trioxide.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Arsenic trioxide.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Arsenic trioxide.]
[S01XA12, dexpanthenol, Arsenic trioxide may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be increased when it is combined with Arsenic trioxide.]
[L01XX72, tazemetostat, The serum concentration of Tazemetostat can be increased when it is combined with Arsenic trioxide.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Teprotumumab.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Arsenic trioxide.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Arsenic trioxide.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ozanimod.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be increased when it is combined with Arsenic trioxide.]
[R02AA03, dichlorobenzyl alcohol, Arsenic trioxide may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Arsenic trioxide may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[M01AH02, rofecoxib, Rofecoxib may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Arsenic trioxide.]
[C08CA16, clevidipine, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Clevidipine.]
[C01BD07, dronedarone, Arsenic trioxide may increase the QTc-prolonging activities of Dronedarone.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Arsenic trioxide.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Arsenic trioxide.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Arsenic trioxide.]
[C02AA06, methoserpidine, Arsenic trioxide may increase the hypotensive activities of Methoserpidine.]
[L01EH03, tucatinib, The serum concentration of Tucatinib can be increased when it is combined with Arsenic trioxide.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Opicapone.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fluprednidene.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L01EX19, ripretinib, The serum concentration of Ripretinib can be increased when it is combined with Arsenic trioxide.]
[V08CA05, mangafodipir, Arsenic trioxide may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Arsenic trioxide.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Arsenic trioxide is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Stepronin.]
[C08CA17, levamlodipine, Arsenic trioxide may increase the hypotensive activities of Levamlodipine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Arsenic trioxide.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Arsenic trioxide.]
[L01FX15, belantamab mafodotin, The serum concentration of Belantamab mafodotin can be increased when it is combined with Arsenic trioxide.]
[L04AC19, satralizumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Satralizumab.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Arsenic trioxide.]
[L01EX23, pralsetinib, The serum concentration of Pralsetinib can be increased when it is combined with Arsenic trioxide.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Arsenic trioxide.]
[N05AA01, chlorpromazine, The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Arsenic trioxide.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Arsenic trioxide.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Arsenic trioxide.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Chlorzoxazone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N02BA03, choline salicylate, Arsenic trioxide may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Arsenic trioxide.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Fludarabine is combined with Arsenic trioxide.]
[L02BX04, relugolix, The serum concentration of Relugolix can be increased when it is combined with Arsenic trioxide.]
[M01AX25, chondroitin sulfates, Arsenic trioxide may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Voclosporin.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Vericiguat.]
[L01EX21, tepotinib, The serum concentration of Tepotinib can be increased when it is combined with Arsenic trioxide.]
[V03AF12, trilaciclib, The serum concentration of Trilaciclib can be increased when it is combined with Arsenic trioxide.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Arsenic trioxide.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C01CA19, fenoldopam, The risk or severity of adverse effects can be increased when Fenoldopam is combined with Arsenic trioxide.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Arsenic trioxide.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Arsenic trioxide.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Arsenic trioxide.]
[N02BG07, flupirtine, Arsenic trioxide may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Arsenic trioxide.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Arsenic trioxide.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Arsenic trioxide.]
[S01LA08, bevacizumab, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Arsenic trioxide.]
[L01EK03, tivozanib, The serum concentration of Tivozanib can be increased when it is combined with Arsenic trioxide.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Arsenic trioxide.]
[H04AA02, dasiglucagon, Arsenic trioxide may increase the hypotensive activities of Dasiglucagon.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Arsenic trioxide.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Arsenic trioxide.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Arsenic trioxide.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Arsenic trioxide.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Arsenic trioxide.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Citalopram is combined with Arsenic trioxide.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Pegcetacoplan.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Belumosudil.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fexinidazole.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Anifrolumab.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Clemastine is combined with Arsenic trioxide.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Arsenic trioxide.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Arsenic trioxide.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ropeginterferon alfa-2b.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Arsenic trioxide.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Arsenic trioxide.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Arsenic trioxide.]
[G03GB02, clomiphene, The serum concentration of Clomifene can be increased when it is combined with Arsenic trioxide.]
[N06AA04, clomipramine, The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Arsenic trioxide.]
[N03AE01, clonazepam, Clonazepam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[S01EA04, clonidine, The risk or severity of adverse effects can be increased when Clonidine is combined with Arsenic trioxide.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Arsenic trioxide.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Deucravacitinib.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Arsenic trioxide.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Granisetron is combined with Arsenic trioxide.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Arsenic trioxide is combined with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be increased when it is combined with Arsenic trioxide.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Arsenic trioxide.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Arsenic trioxide.]
[J01GB12, arbekacin, Arsenic trioxide may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Cocaine.]
[C02KB01, metyrosine, Arsenic trioxide may increase the hypotensive activities of Metyrosine.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Bimekizumab.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[M04AC01, colchicine, The serum concentration of Colchicine can be increased when it is combined with Arsenic trioxide.]
[J01XB01, colistin, Arsenic trioxide may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Arsenic trioxide.]
[A04AA03, tropisetron, Arsenic trioxide may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be decreased when used in combination with Arsenic trioxide.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Arsenic trioxide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nelarabine.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Arsenic trioxide.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Arsenic trioxide.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Arsenic trioxide.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Arsenic trioxide.]
[J05AB14, valganciclovir, Arsenic trioxide may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Arsenic trioxide may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Arsenic trioxide may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Arsenic trioxide may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Arsenic trioxide may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Arsenic trioxide may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C01AA06, lanatoside C, Lanatoside C may decrease the cardiotoxic activities of Arsenic trioxide.]
[N02CC05, almotriptan, Almotriptan may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Arsenic trioxide.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Arsenic trioxide.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Emedastine is combined with Arsenic trioxide.]
[N05BA10, ketazolam, Arsenic trioxide may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Imatinib is combined with Arsenic trioxide.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Arsenic trioxide.]
[C08CA09, lacidipine, Arsenic trioxide may increase the hypotensive activities of Lacidipine.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Arsenic trioxide.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Arsenic trioxide.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Arsenic trioxide.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Arsenic trioxide.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Arsenic trioxide.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C09AA03, lisinopril, The risk or severity of adverse effects can be increased when Lisinopril is combined with Arsenic trioxide.]
[A06AD01, magnesium carbonate, Arsenic trioxide may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, Arsenic trioxide may increase the hypotensive activities of Manidipine.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Meprednisone.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Arsenic trioxide.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Arsenic trioxide.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Arsenic trioxide.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Melperone is combined with Arsenic trioxide.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Arsenic trioxide.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Arsenic trioxide.]
[J05AF07, tenofovir disoproxil, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Arsenic trioxide.]
[L01AA01, cyclophosphamide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Arsenic trioxide.]
[N06AX07, minaprine, Minaprine may increase the orthostatic hypotensive activities of Arsenic trioxide.]
[S01XA18, cyclosporine, Arsenic trioxide may increase the immunosuppressive activities of Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the orthostatic hypotensive activities of Arsenic trioxide.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Arsenic trioxide.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Arsenic trioxide.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC05, moxonidine, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Moxonidine.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Arsenic trioxide.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Arsenic trioxide.]
[M01AH05, etoricoxib, Etoricoxib may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Arsenic trioxide.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be increased when it is combined with Arsenic trioxide.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Arsenic trioxide.]
[C02CC04, debrisoquin, Arsenic trioxide may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Nabilone is combined with Arsenic trioxide.]
[M01AX01, nabumetone, Nabumetone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N07BB05, nalmefene, Arsenic trioxide may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[C07AB12, nebivolol, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nebivolol.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N06AX06, nefazodone, Nefazodone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Arsenic trioxide.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Arsenic trioxide.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Arsenic trioxide.]
[A07EC03, olsalazine, Olsalazine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N06AA01, desipramine, The risk or severity of QTc prolongation can be increased when Desipramine is combined with Arsenic trioxide.]
[C01AA07, deslanoside, Deslanoside may decrease the cardiotoxic activities of Arsenic trioxide.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Arsenic trioxide.]
[V04CH02, indigo carmine, Arsenic trioxide may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C09XA02, aliskiren, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Arsenic trioxide.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Dexamethasone.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Arsenic trioxide.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[B01AC04, clopidogrel, The risk or severity of bleeding can be increased when Clopidogrel is combined with Arsenic trioxide.]
[C01DA05, pentaerythritol tetranitrate, Arsenic trioxide may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[P03AC04, permethrin, Arsenic trioxide may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Diazepam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[V03AH01, diazoxide, The risk or severity of adverse effects can be increased when Diazoxide is combined with Arsenic trioxide.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Cinchocaine.]
[R05DA08, pholcodine, Arsenic trioxide may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, Diclofenac may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Arsenic trioxide.]
[A03AA07, dicyclomine, Dicyclomine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C02DG01, pinacidil, Arsenic trioxide may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Arsenic trioxide.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Arsenic trioxide.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Pipamperone.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ixabepilone.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Arsenic trioxide.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Pirarubicin.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Arsenic trioxide.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Difluocortolone.]
[N02BA11, diflunisal, Diflunisal may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Arsenic trioxide.]
[C01AA05, digoxin, Arsenic trioxide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB01, dihydralazine, Arsenic trioxide may increase the hypotensive activities of Dihydralazine.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Arsenic trioxide.]
[N02AA03, hydromorphone, Hydromorphone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Arsenic trioxide.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Arsenic trioxide.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Arsenic trioxide.]
[H03BC01, potassium perchlorate, Arsenic trioxide may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Pramocaine.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Arsenic trioxide.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Arsenic trioxide.]
[V03AB09, dimercaprol, Arsenic trioxide may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, Dimethyl sulfoxide may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Diphenhydramine.]
[C09AA06, quinapril, The risk or severity of adverse effects can be increased when Quinapril is combined with Arsenic trioxide.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Arsenic trioxide.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Arsenic trioxide.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Cisapride is combined with Arsenic trioxide.]
[C09AA05, ramipril, The risk or severity of adverse effects can be increased when Ramipril is combined with Arsenic trioxide.]
[S01XA23, sirolimus, The serum concentration of Sirolimus can be increased when it is combined with Arsenic trioxide.]
[S01AX06, resorcinol, Arsenic trioxide may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Arsenic trioxide.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Natalizumab.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Arsenic trioxide.]
[S02AA12, rifamycin SV, The serum concentration of Rifamycin can be increased when it is combined with Arsenic trioxide.]
[D06AX11, rifaximin, The serum concentration of Rifaximin can be increased when it is combined with Arsenic trioxide.]
[N05AX08, risperidone, Arsenic trioxide may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Arsenic trioxide.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Arsenic trioxide.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Arsenic trioxide.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Sunitinib.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Arsenic trioxide.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be increased when it is combined with Arsenic trioxide.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C02KX02, ambrisentan, The serum concentration of Ambrisentan can be increased when it is combined with Arsenic trioxide.]
[C01EB18, ranolazine, The serum concentration of Ranolazine can be increased when it is combined with Arsenic trioxide.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Arsenic trioxide.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C01CA07, dobutamine, Dobutamine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Domperidone.]
[C01CA04, dopamine, Dopamine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Arsenic trioxide.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Arsenic trioxide.]
[L01DB01, doxorubicin, The serum concentration of Doxorubicin can be increased when it is combined with Arsenic trioxide.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Arsenic trioxide.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Arsenic trioxide.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Droperidol is combined with Arsenic trioxide.]
[A08AA10, sibutramine, Sibutramine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C10AA01, simvastatin, The serum concentration of Simvastatin can be increased when it is combined with Arsenic trioxide.]
[A12CA02, sodium sulfate, Arsenic trioxide may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, Arsenic trioxide may increase the hypotensive activities of Spirapril.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Sultopride is combined with Arsenic trioxide.]
[N02CC01, sumatriptan, Sumatriptan may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[V04CX07, edrophonium, Edrophonium may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Talinolol is combined with Arsenic trioxide.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Corticotropin.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Temafloxacin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Arsenic trioxide.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[G04CA03, terazosin, The risk or severity of adverse effects can be increased when Terazosin is combined with Arsenic trioxide.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Terodiline.]
[C09AA02, enalapril, The risk or severity of adverse effects can be increased when Enalapril is combined with Arsenic trioxide.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N06AG03, toloxatone, Toloxatone may increase the orthostatic hypotensive activities of Arsenic trioxide.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Arsenic trioxide.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Toremifene is combined with Arsenic trioxide.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA10, trandolapril, The risk or severity of adverse effects can be increased when Trandolapril is combined with Arsenic trioxide.]
[N05CC01, chloral hydrate, Arsenic trioxide may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Arsenic trioxide.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Trilostane is combined with Arsenic trioxide.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Arsenic trioxide.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Arsenic trioxide.]
[C02CA06, urapidil, Arsenic trioxide may increase the hypotensive activities of Urapidil.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Arsenic trioxide.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Arsenic trioxide.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Arsenic trioxide.]
[N06AX16, venlafaxine, Venlafaxine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C08CA12, mepirodipine, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Barnidipine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Arsenic trioxide.]
[C09AA15, zofenopril, Arsenic trioxide may increase the hypotensive activities of Zofenopril.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Arsenic trioxide.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Arsenic trioxide.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Arsenic trioxide.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Arsenic trioxide.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Arsenic trioxide.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Iloprost is combined with Arsenic trioxide.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Arsenic trioxide.]
[L03AX05, pidotimod, Arsenic trioxide may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Arsenic trioxide.]
[N05CD04, estazolam, Arsenic trioxide may decrease the excretion rate of Estazolam which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[G03CA03, estradiol, Estradiol may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Estramustine.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fluticasone.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Amifostine is combined with Arsenic trioxide.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Arsenic trioxide.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Arsenic trioxide.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Etidocaine.]
[N01AX07, etomidate, Etomidate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Arsenic trioxide.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Arsenic trioxide.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Arsenic trioxide.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Arsenic trioxide.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Astemizole is combined with Arsenic trioxide.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Terfenadine is combined with Arsenic trioxide.]
[P01AX07, trimetrexate, Trimetrexate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N06AX12, bupropion, Bupropion may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N06AB08, fluvoxamine, Fluvoxamine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Arsenic trioxide.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Arsenic trioxide.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Arsenic trioxide.]
[C10AA03, pravastatin, The serum concentration of Pravastatin can be increased when it is combined with Arsenic trioxide.]
[M01CB01, gold sodium thiomalate, Arsenic trioxide may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Arsenic trioxide may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Arsenic trioxide.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Arsenic trioxide.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Felodipine is combined with Arsenic trioxide.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Fendiline is combined with Arsenic trioxide.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N02AB03, fentanyl, Fentanyl may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Arsenic trioxide.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Arsenic trioxide.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Arsenic trioxide.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Arsenic trioxide.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[G04BD02, flavoxate, Flavoxate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Flecainide is combined with Arsenic trioxide.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Arsenic trioxide.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Flucytosine is combined with Arsenic trioxide.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Arsenic trioxide.]
[V03AB25, flumazenil, Arsenic trioxide may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Fluocinonide is combined with Arsenic trioxide.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fluocortolone.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Arsenic trioxide.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Arsenic trioxide.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Arsenic trioxide.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Arsenic trioxide.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Arsenic trioxide.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Flupentixol.]
[N05CD01, flurazepam, Flurazepam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Arsenic trioxide.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L01BC03, tegafur, Arsenic trioxide may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[G01AX06, furazolidone, Furazolidone may increase the orthostatic hypotensive activities of Arsenic trioxide.]
[J05AE10, darunavir, The serum concentration of Darunavir can be increased when it is combined with Arsenic trioxide.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, Eszopiclone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Arsenic trioxide.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Arsenic trioxide.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Arsenic trioxide.]
[S01AD09, ganciclovir, Ganciclovir may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Arsenic trioxide.]
[C10AB04, gemfibrozil, Arsenic trioxide may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Telavancin is combined with Arsenic trioxide.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Arsenic trioxide.]
[L01EA02, dasatinib, The serum concentration of Dasatinib can be increased when it is combined with Arsenic trioxide.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Arsenic trioxide.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Arsenic trioxide.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Arsenic trioxide.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Arsenic trioxide.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Arsenic trioxide.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Arsenic trioxide.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Arsenic trioxide.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Arsenic trioxide.]
[C05AE01, nitroglycerin, The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Arsenic trioxide.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Arsenic trioxide.]
[C02CA04, doxazosin, The risk or severity of adverse effects can be increased when Doxazosin is combined with Arsenic trioxide.]
[L01EX02, sorafenib, The risk or severity of adverse effects can be increased when Sorafenib is combined with Arsenic trioxide.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Arsenic trioxide.]
[M01CB04, aurothioglucose, Arsenic trioxide may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Arsenic trioxide may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Fluindione is combined with Arsenic trioxide.]
[C09AA09, fosinopril, The risk or severity of adverse effects can be increased when Fosinopril is combined with Arsenic trioxide.]
[S01EX01, guanethidine, Arsenic trioxide may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Arsenic trioxide.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Arsenic trioxide.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Arsenic trioxide.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Arsenic trioxide.]
[N06BX13, idebenone, Arsenic trioxide may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Arsenic trioxide.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Arsenic trioxide.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Arsenic trioxide.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Arsenic trioxide.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Arsenic trioxide.]
[G03DC01, allylestrenol, Arsenic trioxide may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, Mesalazine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Arsenic trioxide.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Arsenic trioxide.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Arsenic trioxide.]
[M02AA26, nimesulide, The risk or severity of bleeding can be increased when Nimesulide is combined with Arsenic trioxide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Arsenic trioxide.]
[C09AA04, perindopril, The risk or severity of adverse effects can be increased when Perindopril is combined with Arsenic trioxide.]
[C02DB02, hydralazine, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Arsenic trioxide.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Arsenic trioxide may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[G04BD06, propiverine, Arsenic trioxide may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Hydroxychloroquine.]
[B05AA07, hetastarch, Arsenic trioxide may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Arsenic trioxide.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Hydroxyzine.]
[C02AC06, rilmenidine, Arsenic trioxide may increase the hypotensive activities of Rilmenidine.]
[R02AX02, ibuprofen, Ibuprofen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[B05XA08, sodium acetate, Arsenic trioxide may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Arsenic trioxide.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Idarubicin.]
[L01AA06, ifosfamide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ifosfamide.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Arsenic trioxide.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Arsenic trioxide.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Paclitaxel.]
[L01CD03, paclitaxel poliglumex, The risk or severity of cardiotoxicity can be increased when Arsenic trioxide is combined with Paclitaxel poliglumex.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Arsenic trioxide.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Tixocortol.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Arsenic trioxide.]
[L01CE01, topotecan, The serum concentration of Topotecan can be increased when it is combined with Arsenic trioxide.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Arsenic trioxide.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Arsenic trioxide.]
[C02CA02, indoramin, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Indoramin.]
[A11HA07, inositol, Arsenic trioxide may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Arsenic trioxide.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Arsenic trioxide.]
[N06AX17, milnacipran, Arsenic trioxide may decrease the excretion rate of Milnacipran which could result in a higher serum level.]
[S01XA28, varenicline, Arsenic trioxide may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Articaine.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Arsenic trioxide.]
[N05BA12, alprazolam, Alprazolam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N05CH02, ramelteon, Ramelteon may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Arsenic trioxide.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Arsenic trioxide.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Arsenic trioxide.]
[C07AA01, alprenolol, Arsenic trioxide may increase the hypotensive activities of Alprenolol.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Arsenic trioxide.]
[V03AB01, ipecac, Arsenic trioxide may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AF05, iproniazid, Iproniazid may increase the orthostatic hypotensive activities of Arsenic trioxide.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the orthostatic hypotensive activities of Arsenic trioxide.]
[C09AA16, imidapril, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Arsenic trioxide.]
[J04AC01, isoniazid, Isoniazid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J05AX05, inosine pranobex, Arsenic trioxide may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be decreased when used in combination with Arsenic trioxide.]
[C01DA14, isosorbide mononitrate, The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Arsenic trioxide.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Arsenic trioxide.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Isoxsuprine.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Arsenic trioxide.]
[S01AA24, kanamycin, Arsenic trioxide may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Tocilizumab.]
[N01AX03, ketamine, Arsenic trioxide may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Arsenic trioxide.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Arsenic trioxide.]
[J02AB02, ketoconazole, The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Arsenic trioxide.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Arsenic trioxide.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Arsenic trioxide.]
[N04BC09, rotigotine, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Rotigotine.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Arsenic trioxide.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C07AG01, labetalol, The risk or severity of adverse effects can be increased when Labetalol is combined with Arsenic trioxide.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Arsenic trioxide.]
[C02AA05, deserpidine, Arsenic trioxide may increase the hypotensive activities of Deserpidine.]
[A06AX03, lubiprostone, Lubiprostone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Arsenic trioxide.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Arsenic trioxide is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Arsenic trioxide.]
[S01AA21, amikacin, Arsenic trioxide may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Lomustine.]
[A07DA03, loperamide, The excretion of Loperamide can be decreased when combined with Arsenic trioxide.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L01EG01, temsirolimus, The serum concentration of Temsirolimus can be increased when it is combined with Arsenic trioxide.]
[B05XA11, magnesium chloride, Arsenic trioxide may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Arsenic trioxide may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Pralatrexate.]
[L01EA03, nilotinib, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nilotinib.]
[V04CX04, mannitol, The serum concentration of Mannitol can be increased when it is combined with Arsenic trioxide.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Arsenic trioxide.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Arsenic trioxide.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Arsenic trioxide.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C01AA08, medigoxin, Arsenic trioxide may decrease the excretion rate of Metildigoxin which could result in a higher serum level.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Arsenic trioxide.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Arsenic trioxide.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Arsenic trioxide.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Arsenic trioxide.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Melphalan is combined with Arsenic trioxide.]
[N06DX01, memantine, Memantine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N02AB02, meperidine, Meperidine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Arsenic trioxide.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Mepivacaine.]
[G04BX16, tiopronin, Arsenic trioxide may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Arsenic trioxide.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Paliperidone.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Arsenic trioxide.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Arsenic trioxide.]
[N07BC02, methadone, The risk or severity of QTc prolongation can be increased when Methadone is combined with Arsenic trioxide.]
[N06BA03, methamphetamine, Arsenic trioxide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Methimazole is combined with Arsenic trioxide.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Arsenic trioxide.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Arsenic trioxide.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Arsenic trioxide.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Arsenic trioxide.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, The risk or severity of adverse effects can be increased when Methyldopa is combined with Arsenic trioxide.]
[V04CG05, methylene blue, Methylene blue may increase the orthostatic hypotensive activities of Arsenic trioxide.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Arsenic trioxide.]
[G03EK01, methyltestosterone, Arsenic trioxide may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Arsenic trioxide.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, The risk or severity of adverse effects can be increased when Metoprolol is combined with Arsenic trioxide.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Arsenic trioxide.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N02BB03, aminopyrine, Aminophenazone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Arsenic trioxide.]
[N05CD08, midazolam, Midazolam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Mifepristone is combined with Arsenic trioxide.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Arsenic trioxide.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C09CA03, valsartan, The risk or severity of adverse effects can be increased when Valsartan is combined with Arsenic trioxide.]
[D11AX01, minoxidil, The risk or severity of adverse effects can be increased when Minoxidil is combined with Arsenic trioxide.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Mitoxantrone.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Arsenic trioxide.]
[C01BD01, amiodarone, The risk or severity of QTc prolongation can be increased when Amiodarone is combined with Arsenic trioxide.]
[N06AA09, amitriptyline, The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Arsenic trioxide.]
[N02AA01, morphine, The serum concentration of Morphine can be increased when it is combined with Arsenic trioxide.]
[A04AA05, palonosetron, Palonosetron may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, Arsenic trioxide may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ofatumumab.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Arsenic trioxide.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Arsenic trioxide.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Arsenic trioxide.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Arsenic trioxide.]
[G04CA04, silodosin, The excretion of Silodosin can be decreased when combined with Arsenic trioxide.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Arsenic trioxide.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Arsenic trioxide.]
[C07AA12, nadolol, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nadolol.]
[J01CA04, amoxicillin, Amoxicillin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Arsenic trioxide.]
[V03AB15, naloxone, Arsenic trioxide may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Arsenic trioxide.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[M02AA12, naproxen, Naproxen may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be decreased when used in combination with Arsenic trioxide.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Arsenic trioxide is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Arsenic trioxide.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Arsenic trioxide.]
[L01CD02, docetaxel, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Docetaxel.]
[S03AA01, neomycin, Arsenic trioxide may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Arsenic trioxide.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Arsenic trioxide.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Arsenic trioxide.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Arsenic trioxide.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Arsenic trioxide.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L03AX16, plerixafor, Arsenic trioxide may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Arsenic trioxide may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, Arsenic trioxide may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.]
[C09CA07, telmisartan, The risk or severity of adverse effects can be increased when Telmisartan is combined with Arsenic trioxide.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C01CE01, inamrinone, Arsenic trioxide may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Arsenic trioxide.]
[N06AF02, nialamide, Nialamide may increase the orthostatic hypotensive activities of Arsenic trioxide.]
[C08CA04, nicardipine, The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Arsenic trioxide.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Arsenic trioxide.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Amyl Nitrite.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Arsenic trioxide.]
[C08CA07, nisoldipine, The risk or severity of adverse effects can be increased when Nisoldipine is combined with Arsenic trioxide.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Arsenic trioxide.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Arsenic trioxide.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N05CF03, zaleplon, Zaleplon may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N04BC05, pramipexole, The risk or severity of adverse effects can be increased when Pramipexole is combined with Arsenic trioxide.]
[C02DD01, nitroprusside, The risk or severity of adverse effects can be increased when Nitroprusside is combined with Arsenic trioxide.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Arsenic trioxide.]
[C02KX01, bosentan, Arsenic trioxide may increase the hypotensive activities of Bosentan.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Arsenic trioxide.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Arsenic trioxide.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Arsenic trioxide.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Arsenic trioxide.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Arsenic trioxide.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Rilonacept.]
[N02AA02, opium, Arsenic trioxide may decrease the excretion rate of Opium which could result in a higher serum level.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Arsenic trioxide.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Arsenic trioxide.]
[G04CA02, tamsulosin, The risk or severity of adverse effects can be increased when Tamsulosin is combined with Arsenic trioxide.]
[C01AC01, ouabain, Ouabain may decrease the cardiotoxic activities of Arsenic trioxide.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N05BA04, oxazepam, Oxazepam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Arsenic trioxide.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Oxprenolol.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Arsenic trioxide.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Asenapine.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Arsenic trioxide.]
[J04AB30, capreomycin, Arsenic trioxide may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Arsenic trioxide.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Paramethasone.]
[C02KC01, pargyline, Pargyline may increase the orthostatic hypotensive activities of Arsenic trioxide.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Arsenic trioxide.]
[G04BD11, fesoterodine, Arsenic trioxide may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Penfluridol is combined with Arsenic trioxide.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Arsenic trioxide.]
[J01CE09, penicillin G procaine, Arsenic trioxide may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Arsenic trioxide.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Arsenic trioxide.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Arsenic trioxide.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Arsenic trioxide.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Pentoxifylline is combined with Arsenic trioxide.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Arsenic trioxide.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Arsenic trioxide.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may increase the orthostatic hypotensive activities of Arsenic trioxide.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be decreased when used in combination with Arsenic trioxide.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Arsenic trioxide.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Arsenic trioxide.]
[N03AA02, phenobarbital, Phenobarbital may increase the hypotensive activities of Arsenic trioxide.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Arsenic trioxide.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Phenprocoumon is combined with Arsenic trioxide.]
[V03AB36, phentolamine, The risk or severity of adverse effects can be increased when Phentolamine is combined with Arsenic trioxide.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Arsenic trioxide.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Mibefradil is combined with Arsenic trioxide.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Pimozide is combined with Arsenic trioxide.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Arsenic trioxide.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Arsenic trioxide.]
[N06BX03, piracetam, Arsenic trioxide may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of adverse effects can be increased when Eprosartan is combined with Arsenic trioxide.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Arsenic trioxide.]
[C09CA04, irbesartan, The risk or severity of adverse effects can be increased when Irbesartan is combined with Arsenic trioxide.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Arsenic trioxide.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Arsenic trioxide.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Arsenic trioxide.]
[L02BG03, anastrozole, The risk or severity of cardiotoxicity can be increased when Arsenic trioxide is combined with Anastrozole.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Canakinumab.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Arsenic trioxide.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Arsenic trioxide.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Arsenic trioxide.]
[C07AB01, practolol, Arsenic trioxide may increase the hypotensive activities of Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Arsenic trioxide.]
[C02CA01, prazosin, The risk or severity of adverse effects can be increased when Prazosin is combined with Arsenic trioxide.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Arsenic trioxide.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Arsenic trioxide.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Antazoline is combined with Arsenic trioxide.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Arsenic trioxide.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Prilocaine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Primaquine is combined with Arsenic trioxide.]
[N03AA03, primidone, Primidone may increase the hypotensive activities of Arsenic trioxide.]
[M04AB01, probenecid, Probenecid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Probucol is combined with Arsenic trioxide.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Arsenic trioxide.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Arsenic trioxide.]
[C10AB05, fenofibrate, Fenofibrate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Arsenic trioxide.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Promazine is combined with Arsenic trioxide.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Promethazine is combined with Arsenic trioxide.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Arsenic trioxide.]
[A03AB05, propantheline, Propantheline may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[R06AX26, fexofenadine, The serum concentration of Fexofenadine can be increased when it is combined with Arsenic trioxide.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be increased when it is combined with Arsenic trioxide.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Arsenic trioxide.]
[C07AA05, propranolol, The risk or severity of adverse effects can be increased when Propranolol is combined with Arsenic trioxide.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Arsenic trioxide.]
[C01AB01, proscillaridin, Proscillaridin may decrease the cardiotoxic activities of Arsenic trioxide.]
[N02CC04, rizatriptan, Rizatriptan may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[B01AC09, epoprostenol, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Arsenic trioxide.]
[N05AX12, aripiprazole, The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Arsenic trioxide.]
[N07XX07, dalfampridine, Arsenic trioxide may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Arsenic trioxide may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Arsenic trioxide.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Arsenic trioxide.]
[C01BA01, quinidine, The serum concentration of Quinidine can be increased when it is combined with Arsenic trioxide.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Arsenic trioxide.]
[A02BA02, ranitidine, Ranitidine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[C02AA01, rescinnamine, Arsenic trioxide may increase the hypotensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Arsenic trioxide.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Arsenic trioxide.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Arsenic trioxide.]
[S01BC08, salicylic acid, Salicylic acid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Arsenic trioxide.]
[N04BD01, selegiline, Selegiline may increase the orthostatic hypotensive activities of Arsenic trioxide.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Obinutuzumab.]
[J01GB08, sisomicin, Arsenic trioxide may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Arsenic trioxide may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Arsenic trioxide.]
[V04CC01, sorbitol, Arsenic trioxide may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Arsenic trioxide.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be increased when it is combined with Arsenic trioxide.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Arsenic trioxide.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be increased when it is combined with Arsenic trioxide.]
[V09AB03, ioflupane I-123, Arsenic trioxide may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Arsenic trioxide.]
[V09AA01, technetium Tc 99m exametazime, Arsenic trioxide may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Arsenic trioxide may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Arsenic trioxide.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Hydrocortisone butyrate.]
[N05AL01, sulpiride, QT prolonging agents - QT prolonging agents]
[N05AC02, thioridazine, QT prolonging agents - QT prolonging agents]
[L01EX04, vandetanib, QT prolonging agents - QT prolonging agents]
[N06DA02, donepezil, QT prolonging agents - QT prolonging agents]
[S01AE07, moxifloxacin, QT prolonging agents - QT prolonging agents]
[C08EA02, bepridil, QT prolonging agents - QT prolonging agents]
[J01MA09, sparfloxacin, QT prolonging agents - QT prolonging agents]
[S01AA26, azithromycin, QT prolonging agents - QT prolonging agents]
[B01AC23, cilostazol, QT prolonging agents - QT prolonging agents]
[J01FA09, clarithromycin, QT prolonging agents - QT prolonging agents]
[S01AE06, gatifloxacin, QT prolonging agents - QT prolonging agents]
[C01BD07, dronedarone, QT prolonging agents - QT prolonging agents]
[L01DB04, aclarubicin, QT prolonging agents - QT prolonging agents]
[P01BA01, chloroquine, QT prolonging agents - QT prolonging agents]
[N05AA01, chlorpromazine, QT prolonging agents - QT prolonging agents]
[N05AF03, chlorprothixene, QT prolonging agents - QT prolonging agents]
[S03AA07, ciprofloxacin, QT prolonging agents - QT prolonging agents]
[N06AB04, citalopram, QT prolonging agents - QT prolonging agents]
[L01EB10, mobocertinib, QT prolonging agents - QT prolonging agents]
[A04AA01, ondansetron, QT prolonging agents - QT prolonging agents]
[S02DA02, cocaine, QT prolonging agents - QT prolonging agents]
[C01BA13, hydroquinidine, QT prolonging agents - QT prolonging agents]
[P01CB01, meglumine antimoniate, QT prolonging agents - QT prolonging agents]
[L01XA03, oxaliplatin, QT prolonging agents - QT prolonging agents]
[A03FA02, cisapride, QT prolonging agents - QT prolonging agents]
[C01BA03, disopyramide, QT prolonging agents - QT prolonging agents]
[A03FA03, domperidone, QT prolonging agents - QT prolonging agents]
[N01AB08, sevoflurane, QT prolonging agents - QT prolonging agents]
[N05AD08, droperidol, QT prolonging agents - QT prolonging agents]
[N05AL02, sultopride, QT prolonging agents - QT prolonging agents]
[G04BD05, terodiline, QT prolonging agents - QT prolonging agents]
[S01AA17, erythromycin, QT prolonging agents - QT prolonging agents]
[C01BD05, ibutilide, QT prolonging agents - QT prolonging agents]
[N05AE03, sertindole, QT prolonging agents - QT prolonging agents]
[R06AX11, astemizole, QT prolonging agents - QT prolonging agents]
[R06AX12, terfenadine, QT prolonging agents - QT prolonging agents]
[C01BC04, flecainide, QT prolonging agents - QT prolonging agents]
[J02AC01, fluconazole, QT prolonging agents - QT prolonging agents]
[C01BD04, dofetilide, QT prolonging agents - QT prolonging agents]
[P01BX01, halofantrine, QT prolonging agents - QT prolonging agents]
[N05AD01, haloperidol, QT prolonging agents - QT prolonging agents]
[P01BA02, hydroxychloroquine, QT prolonging agents - QT prolonging agents]
[H01BA04, terlipressin, QT prolonging agents - QT prolonging agents]
[L01XX35, anagrelide, QT prolonging agents - QT prolonging agents]
[N05AC03, mesoridazine, QT prolonging agents - QT prolonging agents]
[N07BC02, methadone, QT prolonging agents - QT prolonging agents]
[N05AA02, methotrimeprazine, QT prolonging agents - QT prolonging agents]
[C01BD01, amiodarone, QT prolonging agents - QT prolonging agents]
[S01AE05, levofloxacin, QT prolonging agents - QT prolonging agents]
[N05AG02, pimozide, QT prolonging agents - QT prolonging agents]
[J01MA11, grepafloxacin, QT prolonging agents - QT prolonging agents]
[C10AX02, probucol, QT prolonging agents - QT prolonging agents]
[C01BA02, procainamide, QT prolonging agents - QT prolonging agents]
[N01AX10, propofol, QT prolonging agents - QT prolonging agents]
[C01BA01, quinidine, QT prolonging agents - QT prolonging agents]
[J01FA06, roxithromycin, QT prolonging agents - QT prolonging agents]
[C07AA07, sotalol, QT prolonging agents - QT prolonging agents]
